Chromosome 13 abnormalities identified by FISH analysis and serum β2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy

Blood

Volumn 97, Issue 6, 2001, Pages 1566-1571

  Facon, Thierry ^a   Avet Loiseau, Hervé ^b   Guillerm, Gaëlle ^b   Moreau, Philippe ^b   Geneviève, Franck ^b   Zandecki, Marc ^b   Laï, Jean Luc ^b   Leleu, Xavier ^b   Jouet, Jean Pierre ^b   Bauters, Francis ^b   Harousseau, Jean Luc ^b   Bataille, Régis ^b   Mary, Jean Yves ^b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; MELPHALAN; VINCRISTINE;

ADULT; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 13; CHROMOSOME ABERRATION; DIAGNOSTIC ACCURACY; DRUG MEGADOSE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; MAJOR CLINICAL STUDY; MYELOMA; PRIORITY JOURNAL; TREATMENT PLANNING;

EID: 0035869257     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.6.1566     Document Type: Article

References (35)

1. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
2. Serum β2 microglobulin and survival duration in multiple myeloma: A simple reliable marker for staging
3. β2-Microglobulin in myeloma: Optimal use for staging, prognosis, and treatment: A prospective study of 160 patients
4. Pretreatment serum β2-microglobulin in multiple myeloma
5. Prognostic value of pretreatment serum β2 microglobulin in myeloma: A Southwest Oncology Group Study
6. Serum β2-microglobulin in the initial staging and subsequent monitoring of monoclonal plasma cell disorders
7. Autologous bone marrow transplantation in multiple myeloma: Identification of prognostic factors
8. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities
9. Autotransplants in multiple myeloma: What have we learned?
10. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants
11. Total therapy with tandem transplants for newly diagnosed multiple myeloma
12. Prognostic value of cytogenetics in multiple myeloma
13. Results of high-dose therapy for 1000 patients with multiple myeloma: Durable complete remissions and superior survival in the absence of chromosome 13 abnormalities
14. Predictive value of interphase cytogenetics for survival of patients with multiple myeloma
15. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization
16. Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma
17. Prognostic value of numerical chromosome aberrations in multiple myeloma: A FISH analysis of 15 different chromosomes
18. Improved cytogenetics in multiple myeloma: A study of 151 patients including 117 patients at diagnosis
19. Monoclonal gammopathy of undetermined significance: Chromosome changes are a common finding within bone marrow plasma cells
20. Non parametric estimation from incomplete observations
21. Evaluation of survival data and two new rank order statistics arising in its consideration
22. Regression models and life-tables
23. Design and analysis of randomized clinical trials requiring prolonged observation of each patient; II, analysis and examples
24. Identification of prognostic factors
25. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system
26. High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH
27. Interphase fluorescence in situ hybridization (FISH) as a powerful tool for the detection of aneuploidy in multiple myeloma
28. Multiple myeloma: High incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization
29. Multiple myeloma: Almost all patients are cytogenetically abnormal
30. Staging and kinetics of multiple myeloma
31. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma
32. Antitumor activity of thalidomide in refractory multiple myeloma